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Abstract
Background: The onset of cachexia is a frequent feature in cancer patients. Prominent characteristic of this syndrome is the
loss of body and muscle weight, this latter being mainly supported by increased protein breakdown rates. While the
signaling pathways dependent on IGF-1 or myostatin were causally involved in muscle atrophy, the role of the Mitogen-
Activated-Protein-Kinases is still largely debated. The present study investigated this point on mice bearing the C26 colon
adenocarcinoma.
Methodology/Principal Findings: C26-bearing mice display a marked loss of body weight and muscle mass, this latter
associated with increased phosphorylated (p)-ERK. Administration of the ERK inhibitor PD98059 to tumor bearers attenuates
muscle depletion and weakness, while restoring normal atrogin-1 expression. In C26 hosts, muscle wasting is also associated
with increased Pax7 expression and reduced myogenin levels. Such pattern, suggestive of impaired myogenesis, is reversed
by PD98059. Increased p-ERK and reduced myosin heavy chain content can be observed in TNFa-treated C2C12 myotubes,
while decreased myogenin and MyoD levels occur in differentiating myoblasts exposed to the cytokine. All these changes
are prevented by PD98059.
Conclusions/Significance: These results demonstrate that ERK is involved in the pathogenesis of muscle wasting in cancer
cachexia and could thus be proposed as a therapeutic target.
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Introduction
Cancer cachexia is a multifactorial, multifaceted syndrome, in
particular characterized by marked loss of body weight, depletion
of fat and muscle mass and protein hypercatabolism in many
tissues. The onset of cachexia is clinically relevant since it
complicates patients’ management by both increasing morbidity
and mortality rates and reducing the tolerance to antineoplastic
treatments. Anorexia, inflammation and altered hormonal ho-
meostasis significantly contribute to the pathogenesis of cancer
cachexia.
Skeletal muscle wasting is a major feature of cachexia. Among
the underlying mechanisms, a prominent role is played by the
onset of a sustained hypercatabolic response not directly related to
the tumor-host metabolic needs. The enhanced muscle protein
degradation relies on the activity of different proteolytic systems.
The ubiquitin and proteasome system (UPS), in particular, seems
to play a major role [1], although additional proteolytic pathways
were proposed to act upstream and downstream of the UPS to
accomplish complete breakdown of myofibrillar proteins [2].
Finally, a role for the autophagic-lysosomal degradation has been
revisited [3]. Other mechanisms possibly accounting for muscle
depletion in cancer cachexia are downregulation of protein
synthesis rates[4], or an impaired myogenic regenerative response
[5].
Recently, specific signaling pathways have been suggested to
contribute to muscle atrophy. In this regard, downregulated IGF1
signaling was associated with muscle atrophy by denervation,
immobilization, unloading, starvation, aging, and prolonged
glucocorticoid administration [6]. By contrast, the activation
status of the IGF1-dependent signaling was not impaired in the
skeletal muscle of tumor-bearing animals [7]. This observation led
to search for alternative signaling pathways that might be relevant
to the pathogenesis of muscle depletion in experimental cancer
cachexia. Keeping in mind that proinflammatory factors play a
pivotal role in mediating muscle wasting, the attention was focused
on cytokine-dependent signals, in particular those activated by
Mitogen-Activated Protein Kinases (MAPKs).
Four main MAPKs have been identified in mammals: JNK (1–
3), p38 (a-d), ERK 1/2 (hereafter referred to as ERK) and ERK5
[8]. MAPKs are activated by phosphorylation of both threonine
and tyrosine residues by MAPK-kinases and inactivated by specific
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phosphatases such as the MAPK-phosphatase 1 [8]. Both MAPKs
and phosphatases participate in the regulation of muscle growth
and function [9]. p38 activation is necessary for muscle
development which leads to phosphorylation of substrates involved
in the myogenic process. In particular, p38 was shown to affect the
expression of myogenic regulatory factors (MRFs), such as Myf5,
and the activities of transcription factors belonging to the MEF2
and MyoD families. In addition, p38 was demonstrated to inhibit
ERK, thereby withdrawing myocytes from the cell cycle, while
ERK inhibition resulted in marked induction of p38 activity [9].
The interaction between p38 and ERK was proposed to drive the
p38-dependent growth arrest and myogenic differentiation in
rhabdomyosarcoma cells [10]. In a similar way, ERK activation
was shown to inhibit myotube formation, repressing skeletal
myogenesis [11]. A recent study reported that ERK is more active
in fast- than in slow-twitch muscles [12], suggesting that this
activity could be necessary to maintain the fast-twitch phenotype.
Subsequently, the same group showed that inhibition of MAPK
signaling is associated with reduced expression of fast fiber-specific
genes and with a shift towards the slow-twitch fiber phenotype
[13]. These observations are in contrast with a previous report
showing that in the regenerating soleus muscle the activity of the
Ras-ERK pathway is needed to support the production of slow
myosin heavy chain (MyHC) [14].
The present study aimed to investigate the involvement of
MAPKs in the pathogenesis of muscle depletion in mice bearing
the C26 carcinoma. Transplantation of the C26 tumor to a host
mouse causes a significant loss of body weight and muscle mass
and closely reproduces the clinical features of cancer-induced
muscle wasting [7,15]. The results reported in the present paper
point to ERK as a critical contributor to muscle atrophy in
experimental cancer cachexia.
Materials and Methods
All materials were supplied by Sigma (St. Louis, MO, USA),
unless differently specified.
Ethics statement
Experimental animals were cared for in compliance with the
Italian Ministry of Health Guidelines (nu 86609 EEC, permit
number 106/2007-B) and the Policy on Humane Care and Use of
Laboratory Animals (NIH 1996). The experimental protocol was
approved by the Bioethical Committee of the University of
Torino.
Animals and experimental design
Male Wistar rats weighing about 150 g and Balb-c mice
weighing about 20 g were obtained from Charles River Labora-
tories, Inc. (Calco, LC, Italy) and maintained on a regular dark-
light cycle (light from 08:00 to 20:00), with free access to food
(Piccioni, Brescia, Italy) and water during the whole experimental
period.
Tumor-bearing rats (n = 8) received an intraperitoneal inocu-
lum of Yoshida AH-130 ascites hepatoma cells (,108 cells/rat),
while tumor-bearing mice (n = 8) were inoculated s.c. dorsally with
56105 C26 undifferentiated carcinoma cells. Healthy rats or mice
inoculated with vehicle (saline) served as controls (n = 6).
In another set of experiments, animals were randomized and
divided into four groups, namely controls (C, n = 6) and tumor
bearers (TB, n = 8), treated or not with the MEK inhibitor
PD98059 (PD). PD groups received daily s.c. injections of
PD98059 (1 or 3 mg/kg, Calbiochem, La Jolla, CA, USA). In
particular, rats bearing the AH-130 tumor received 3 mg/kg
PD98059. As for the C26 hosts, two different experiments were
performed, treating the animals with 1 or 3 mg/kg PD98059.
Untreated animals received an equal amount (100 ml) of vehicle
(saline containing 2% DMSO).
Fore and hindlimb grasping strength was measured by means of
a grip strength meter (Columbus Instruments, Columbus, OH,
USA).
Animal weight and food intake were recorded daily. Tumor-
bearing rats and mice were sacrificed under anesthesia 4 and 13
days after tumor transplantation, respectively. Several muscles
were rapidly excised, weighed, frozen in isopentane cooled with
liquid nitrogen and stored at 280uC.
Cell cultures
Murine C2C12 skeletal myoblasts (ATCC, Manassas, VA,
USA) were grown in high glucose Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% FBS, 100 U/ml
penicillin, 100 mg/ml streptomycin, 100 mg/ml sodium pyruvate,
2 mM L-glutamine, and maintained at 37uC in a humidified
atmosphere of 5% CO2 in air. Differentiation was induced by
shifting sub-confluent cultures to DMEM supplemented with 2%
horse serum (differentiation medium; DM). The medium was
changed every 2nd day. On day 0 or 5 of differentiation, the cells
were exposed to TNFa (100 ng/ml; Immunological Sciences,
Rome, Italy) or to 20 mM PD98059, or both, and collected after
48 h; untreated cells served as control.
Plasmids and transfection
The pBabe-Puro Myc-Follistatin plasmid (kindly provided by
Vittorio Sartorelli, NIH, Bethesda, USA) was purified with a
NucleoBond Xtra Maxi kit (Macherey-Nagel GmbH, Duren,
Germany). Transfection was performed with the GeneJuice
reagent (EMD Biosciences, Madison, WI, USA) following
manufacturer instructions. Transfected cells were selected by
adding puromycin at the final concentration of 1 mg/ml.
Immunofluorescence
Transverse sections (10 mm) from the midbelly region of the
tibialis anterior muscle were cut on a Leitz 1720 cryostat (Leica,
Wetzlar, Germany) and fixed in 4% paraformaldehyde. C2C12
monolayers were washed with PBS and fixed in acetone-methanol
(1:1). Samples were then probed with the following primary
antibodies: Laminin from Sigma (St. Louis, MO, USA), Pax7 from
the Hybridoma Bank (University of Iowa) and caveolin-1 from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Detection was
performed using a Cy3-conjugated mouse IgG secondary antibody
(GE Healthcare, Milano, Italy) or a FITC-conjugated rabbit IgG
secondary antibody. Nuclei were stained with the DAPI
fluorochrome and the images captured in an epiilluminated
fluorescence microscope (Axiovert 35, Zeiss, Germany).
ELISA
IL-6 serum levels were detected by a commercially available
mouse ELISA kit, used according to the manufacturer instructions
(Bender MedSystems, Vienna, Austria). Serum from each animal
(50 ml) was assayed in duplicate. Quantitative calibration was
obtained performing a standard curve with recombinant mouse
IL-6.
Western blotting
About 50 mg of muscle were homogenized in 80 mM Tris-HCl,
pH 6.8, containing 100 mM DTT, 70 mM SDS, and 1 mM
glycerol, with freshly added protease and phosphatase inhibitor
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cocktails, kept on ice for 30 min, centrifuged at 15000 x g for
10 min at 4uC, and the supernatant collected. Protein concentra-
tion was assayed using BSA as working standard. C2C12 cells
were lysed on RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM
NaCl, 1% NP40, 0.25% Na-deoxycholate, 1 mM PMSF) with
freshly added protease and phosphatase inhibitor cocktails. Equal
amounts of protein (30 mg) were heat-denaturated in sample-
loading buffer (50 mM Tris-HCl, pH 6.8, 100 mM DTT, 2%
SDS, 0.1% bromophenol blue, 10% glycerol), resolved by SDS-
PAGE and transferred to nitrocellulose membranes (Bio-Rad,
Hercules, CA, USA). The filters were blocked with Tris-buffered
saline (TBS) containing 0.05% Tween and 5% non-fat dry milk
and then incubated overnight with antibodies directed against: p-
ERK (Tyr204), ERK, JNK, p-p38 (Tyr182), follistatin, MyoD, and
myogenin (Santa Cruz Biotechnology, CA, USA), p-JNK (Thr183/
Tyr185), p-c-Jun (Ser73) and p-Akt (Ser473) (Cell Signaling
Technology, Danvers, MA, USA), p38 (Calbiochem, La Jolla,
CA, USA), MyHC and tubulin (Sigma, St. Louis, MO, USA),
atrogin-1 (ECMbiosciences, Versailles, KY, USA) and the
monoclonal antibody against Pax7 developed by Atsushi Kawa-
kami, obtained from the Developmental Studies Hybridoma Bank
(University of Iowa). Peroxidase-conjugated IgG (Bio-Rad,
Hercules, CA, USA) was used as secondary antibodies. Mem-
brane-bound immune complexes were detected by an enhanced
chemiluminescence system (Santa Cruz Biotechnology, USA) on a
photon-sensitive film (Hyperfilm ECL, GE Healthcare, Milano,
Italy). Protein loading was normalized according to tubulin
expression. Specificity of each antibody was tested with positive
and negative controls. Quantification of the bands was performed
by densitometric analysis using a specific software (TotalLab,
NonLinear Dynamics, Newcastle upon Tyne, UK).
Data analysis and presentation
All results were expressed as mean 6 SD. Representative
western blots show independent samples. Significance of the
differences was evaluated by analysis of variance (ANOVA)
followed by Tukey’s test.
Results
Tumor growth in rats bearing the AH-130 hepatoma or mice
bearing the C26 carcinoma is associated with progressive loss of
body and skeletal muscle wet weight. Activation of a sustained
protein hypercatabolic response mainly accounts for muscle
depletion [7].
MAPK expression and phosphorylation status, this latter widely
considered a reliable indicator of MAPK activation [8], were
evaluated in the gastrocnemius muscle of two experimental models
of cancer cachexia. Marked phosphorylation of ERK occurs both
in tumor-bearing (TB) rats and mice, reaching levels respectively
90% and 50% higher than in controls. In contrast, JNK and p38
phosphorylation does not change (Fig. 1A, 1B).
ERK inhibition prevents muscle wasting in the C26 hosts
To assess the relevance of ERK activation to muscle wasting,
TB mice were treated with the MEK inhibitor PD98059 (PD)
[16]. As Fig. 2A shows, daily PD administration (1 mg/kg) to C26
hosts significantly prevents body weight loss (body weight on
day 13: C= 19.861.5 g; C26= 16.760.9 g, p vs C=0.0005;
PD=19.761.8 g; C26-PD=18.361.6 g, p vs C=0.018, p vs
C26= 0.032; n indicated in figure legend), though not affecting
tumor growth (C26= 249657 mg; C26-PD=237631 mg).
Moreover, treatment with PD effectively improves the depletion
of gastrocnemius and tibialis anterior (Fig. 2B) as well as the
muscle grip strength (Fig. 2C). When PD is administered at a
dosage of 3 mg/kg, which closely reproduces the concentration
adopted by the intramuscular infusion study from Haddad et al.
[17], the protective effects reported above are not potentiated any
further (Fig. S1). PD-administered AH-130 bearers (3 mg/kg for 4
days) display a pattern comparable to that observed in the C26
hosts receiving the inhibitor (Fig. S2).
Cachexia induced by the C26 tumor appears to depend on
elevated interleukin (IL)-6 plasma levels [18]. The present work
confirms that circulating IL-6 markedly increases in the C26 hosts,
yet PD administration does not prevent this increase (Fig. S3).
To ascertain if PD prevents muscle wasting by downregulating
the UPS, protein levels of atrogin-1/MAFbx, a muscle-specific
ubiquitin ligase overexpressed in pathological states associated
with muscle atrophy [4,7], were evaluated. Atrogin-1 expression in
the gastrocnemius of TB mice is 35% higher than in controls and
is slightly reduced by PD treatment (Fig. 2D).
PD98059 inhibits TNFa-induced myofibrillar protein loss
in C2C12 myotubes
To investigate if the proinflammatory cytokine TNFa modu-
lates ERK activation in muscle cells, C2C12 myotubes (5 days in
DM) were treated with TNFa for 48 h. As a result, p-ERK levels
increase, while both myotube size and MyHC content are
reduced. Such changes are significantly inhibited by treatment
with PD (Fig. 3A-B). TNFa-induced loss of MyHC is not
associated with reduced p-Akt levels, that remain close to control
values in cultures either treated or not with PD. Finally, the early
(6 h) increase of atrogin-1 expression caused by TNFa is only
slightly, but not significantly, attenuated by PD treatment (Fig. 3B).
ERK activation in TNFa-treated C2C12 myotubes does
not depend on myostatin
To verify if TNFa-induced ERK activation might relate to
myostatin, C2C12 myoblasts were stably transfected with a vector
coding for the endogenous myostatin inhibitor follistatin. No
reduction in size or MyHC content occurs in follistatin-
overexpressing myotubes treated with TNFa (Fig. 4A-B), although
in the latter the degree of ERK activation is similar to that in
TNFa-treated non-transfected cells (Fig 4B). On the other hand,
follistatin overexpression resulted in increased p-Akt levels,
irrespective of the presence of TNFa in the culture medium
(Fig. 4B).
PD98059 prevents satellite cell accumulation in the
muscle of C26 hosts
Apart from protein hypercatabolism, muscle wasting could also
arise from alterations in the myogenic process. In this regard,
aging or hindlimb suspension-induced muscle atrophy are
associated with loss of myofiber precursor cells [19]. The present
report suggest for the first time that impaired myogenesis
significantly contributes to the onset of muscle wasting in cancer
cachexia. In the tibialis anterior of the C26 hosts we indeed
detected by immunofluorescence microscopy increased levels of
Pax7 and caveolin-1 (Fig. 5A), two markers of undifferentiated
cells. Pax7 accumulation, also confirmed by western blotting, is
largely prevented by PD administration (Fig. 5B).
MyoD levels, previously reported to be reduced in the muscle
of AH-130 bearers [20], are unaffected in the gastrocnemius of
the C26 hosts (Fig. 5B), while the marked decrease of myogenin
is rescued by PD treatment (Fig. 5B). Of interest, two myogenin
isoforms can be observed in the TB muscles (Fig. 5B). The one
characterized by a slightly higher molecular weight virtually
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disappears in the PD-treated groups (Fig. 5B) as well as in PD-
untreated TB muscles when cell lysates are incubated in the
presence of phosphatase (Fig. S4). These observations point
to myogenin phosphorylation as a putative mechanism for
impaired muscle regenerative response in cancer cachexia. In
this regard, phosphorylation in the myogenin transcriptional
domain was shown to inhibit the induction of muscle specific
genes [21].
ERK inhibition rescues C2C12 myoblasts from
TNFa-induced impaired differentiation
To better appreciate the role of ERK activation in the
regulation of the myogenic program, C2C12 myocytes were
exposed to TNFa and PD during the first 48 h in differentiation
medium. TNFa enhances ERK phosphoryation, while PD
suppresses this effect (Fig. 6B). PD treatment increases MyHC
accumulation independently of the presence of TNFa, as shown
by both immunofluorescence microscopy and western blotting
(Fig. 6A-B). Differently from fully differentiated cells (see Fig. 3B),
exposure to the cytokine significantly reduces p-Akt levels and this
change is only marginally affected by PD (Fig. 6B). MyoD and
myogenin markedly decrease after TNFa exposure and Pax7
expression is virtually abrogated, yet in the presence of PD both
MyoD and myogenin maintain control levels, while rescue of Pax7
depletion is only partial (Fig. 6B).
Discussion
The present study provides the first report that enhanced
activity of the MAPK ERK occurs in wasting muscles in the course
of experimental cancer cachexia, resulting in atrogin-1 hyper-
expression and likely in reduced regenerative potential. Impor-
tantly, pharmacological inhibition of ERK in C26 carcinoma-
bearing mice markedly attenuates muscle depletion and improves
muscle function, without modifying tumor growth or IL-6
circulating levels. This latter observation suggests that the effects
observed at the muscle level might not depend on systemic IL-6.
ERK involvement in muscle wasting
The role of ERK in the pathogenesis of skeletal muscle atrophy
is quite controversial. Indeed, ERK inactivation resulted in rat
soleus and gastrocnemius atrophy [22] and inhibited fast muscle
hypertrophy induced in experimental animals by b2-adrenergic
agonists or IGF-1 [12,17]. In addition, reduced levels of
phosphorylated ERK were demonstrated during sarcopenia of
aging [23]. A recent study shows that ERK activity significantly
contributes to the protective effect exerted by IGF-1 against
oxidative stress-induced damage in both C2C12 and L6 myocytes
[24]. The myogenic regenerative capacity of human satellite cells
isolated from both young and old subjects was significantly
enhanced when ERK is activated by the presence of FGF in the
culture medium. Consistently, both young and old satellite cells
Figure 1. ERK is activated in the skeletal muscle of TB animals. Levels of phosphorylated MAPKs in the GSN. Panel A: control (C; n = 6) and AH-
130-bearing rats (n = 8). Panel B: control (C, n = 8) and C26-bearing mice (n = 8). Levels of phosphorylation were normalized by total protein content.
Data (means 6 SD) expressed as percentages of controls. Significance of the differences: *p,0.05 vs C.
doi:10.1371/journal.pone.0013604.g001
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failed to produce proliferating fusion-competent myoblasts when
ERK was pharmacologically inhibited [23]. Finally, even if not
sufficient to lead to myogenesis or muscle hypertrophy, ERK
activation regulates satellite cell proliferation, likely contributing to
muscle regeneration and hypertrophy [14].
By contrast, increased ERK activation was reported in muscle
atrophy induced by hind-limb suspension [25]. In C2C12
myotubes ERK activation resulted in reduced myotube size
[16], while ERK inhibition induced a hypertrophic phenotype
similar to that elicited by IGF-1 [16]. Similarly, C2C12 myotube
cultures subjected to 3D-clinorotation showed an overexpression
of both atrogin-1 and MuRF1 ubiquitin ligases, associated with
increased levels of phosphorylated ERK [26].
Muscle wasting mainly depends on protein hypercatabolism in
which the UPS seems to play a major role [1]. Enhanced UPS-
dependent protein breakdown has been associated with downreg-
ulation of the IGF1-dependent PI3K/Akt pathway [6], yet the
latter is not reduced in the skeletal muscle of tumor-bearing
animals [7]. Besides the PI3K/Akt/FoxO signaling, however,
other pathways can trigger atrogenes transcription [27]. In this
regard, still unclear is the relevance of ERK to the induction of
ubiquitin ligases and of the protein hypercatabolic state. In C2C12
myotubes, ERK inhibition appeared required to stimulate
ubiquitin ligase expression [13]. Finally, ubiquitin hyperexpression
induced by glucocorticoids in L6 myotubes was shown to depend
on the activity of both MEK, the kinase upstream of ERK, and the
Sp1 transcription factor [28].
Relevance of TNFa and myostatin to ERK activation
ERK can be activated in the skeletal muscle by several factors,
such as cytokines, myostatin, or IGF-1. As for the latter, its
contribution to muscle atrophy in cancer cachexia has been
already discussed [7]. In the present study we investigated if the
proinflammatory cytokine TNFa activates ERK in C2C12
myotube cultures, and whether myostatin is involved in such
activation. In this regard, muscle wasting in experimental cancer
cachexia was recently suggested to be associated with myostatin
upregulation [29,30]. Similarly, the size reduction caused by
TNFa in cultured C2C12 myotubes is accompanied by increased
myostatin expression [31]. Finally, myostatin was proposed to
activate ERK and to repress the differentiation program in
differentiating C2C12 myocytes [32]. In the present study, we
show that TNFa caused a marked reduction in myotube size
associated with early increased atrogin-1 expression, calpain
hyperactivation (C= 1.21*102362.3*1025 nkat/mg protein,
TNFa=2.01*102362.7*1025 nkat/mg protein, n = 6, p,0.001;
see also [33]), and reduced MyHC content, likely due to enhanced
Figure 2. PD98059 counteracts the onset of cachexia in C26-bearing mice. (A) Body weight, expressed as percent changes respect to initial
body weight (i.b.w., C = 19.1461.68 g; C26 = 19.1460.69 g; PD=18.5762.37 g; C26 PD= 17.5660.89 g), (B) muscle weight, (C) voluntary strength
(grasping test), (D) atrogin-1 and p-c-Jun protein expression in the GSN of controls (n = 6) and C26 hosts (n = 8) either untreated or administered PD
(1 mg/kg; see Materials and methods). Densitometric quantifications were normalized according to tubulin levels. Data (means 6 SD) expressed as
percentages of controls. Significance of the differences: *p,0.05 vs C; **p,0.01 vs C; ***p,0.001 vs C; $ p,0.05 vs C26; $$ p,0.01 vs C26.
doi:10.1371/journal.pone.0013604.g002
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myofibrillar protein breakdown. ERK inhibition prevented TNFa-
induced changes of myotube size, MyHC content and calpain
activity, with a mechanism independent from Akt. This finding is
of particular interest in that confirming that atrogin-1 expression
and protein breakdown are not regulated by the PI3K/Akt
pathway only [6]. The pattern induced by TNFa in C2C12
myotubes closely resembles that observed in the C26 tumor-
bearing mice and points to ERK signaling as to another pathway
by which proinflammatory cytokines may induce muscle wasting.
In this regard, the observations that ERK inhibition in TNFa-
treated C2C12 myotubes does not result in modulations of p-Akt,
and that ERK is activated in the muscle of the C26 hosts in the
absence of any downregulation of p-Akt are intriguing. In fact,
although a reciprocal regulation between ERK and Akt has been
reported [16,34], it has not been clearly established in skeletal
muscle. In this regard, treatment with PD98059 increases p70S6K
activity in L6 myocytes, suggesting that ERK activity results in
PI3K/Akt pathway inhibition [35]. By contrast, in the stretched
diaphragm muscle, increased p-ERK is dependent on PI3K
activity [36], and supplementing serum-starved myoblasts with b-
hydroxy-b-methylbutyrate results in increased proliferation and
reduced apoptosis due to enhanced phosphorylation of both ERK
and Akt [37]. Finally, muscle atrophy induced by conditional
activation of Met is associated with increased Akt activation that,
at least in isolated myotubes, is paralleled by high levels of p-ERK
[38]. Along with other observations showing that biochemical and
molecular alterations in the skeletal muscle of cancer patients are
detectable even before any evidence of body weight loss [39], these
findings suggest that, depending on the situation, the interplay
between ERK and Akt might be crucial to preserve muscle mass
or to drive the muscle towards atrophy. On this line, ERK
activation could be viewed as a compensatory mechanism aimed
at increasing satellite cell proliferation.
Myostatin was shown to activate the ERK-dependent pathway
[32]. Consistently, ERK activation is associated with myostatin
upregulation both in the muscle of tumor-bearing animals [15,29]
and in TNFa-treated C2C12 myotubes[31], suggesting the
possibility of a causal relationship between the two events. The
results shown in the present study, however, render this hypothesis
unlikely, at least concerning C2C12 myotubes exposed to TNFa.
In C2C12 differentiated myocytes, hyperexpression of follistatin, a
physiological inhibitor of myostatin, indeed rescues TNFa-induced
alterations in terms both of myotube size and of MyHC content.
Nevertheless, although the effects of follistatin hyperexpression are
phenotypically comparable to those exerted by ERK inhibition,
the mechanisms involved are quite different. While PD restores
myotube size and MyHC content by blocking ERK without
affecting Akt activity, the opposite occurs in follistatin-hyperex-
pressing cultures, wherein ERK activation remains comparable to
non-transfected TNFa-treated myotubes and p-Akt levels mark-
edly increase. This latter observation is in line with previous
reports showing that myostatin can lead to inhibition of the PI3K/
Figure 3. ERK inhibition prevents TNFa-induced alterations in C2C12 myotube cultures. C2C12 myotubes (5 days differentiation) treated
for 48 h with 100 ng/ml TNFa, in the presence or in the absence of PD (20mM). (A) MyHC immunostaining (red: MyHC; blue: nuclei). (B) Protein
expression levels of p-ERK, MyHC, p-Akt and atrogin-1, the latter two evaluated at both 6 and 48 h (see Li et al., 2005). Densitometric quantifications
were normalized according to tubulin levels. Data (means 6 SD; n= 3) expressed as percentages of controls. Significance of the differences: *p,0.05
vs C; $ p,0.05 vs TNFa.
doi:10.1371/journal.pone.0013604.g003
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Akt pathway [40] and, conversely, myostatin blockade results in
increased p-Akt levels [41].
ERK impinges on myocyte differentiation both in vivo
and in vitro
The improved muscle trophism resulting from ERK inhibition
appears achieved, at least in part, by prevention of atrogin-1
hyperexpression that likely depends on proinflammatory cytokines.
However, the increase in atrogin-1 expression, although signifi-
cant, is not really prominent, suggesting that other mechanisms are
likely to contribute to muscle wasting in the C26 hosts.
Among the targets of ERK is the AP-1 transcription factor,
which is activated in tumor-bearing animals [20] and may
contribute to muscle atrophy, since this latter is improved
inhibiting AP-1 by a c-jun dominant negative (TAM67) [42].
Little is known about the role that genes regulated by AP-1 may
play in muscle depletion. An intriguing hypothesis is that, by
inducing cyclin D1 expression [42], AP-1 could stimulate satellite
cell proliferation not followed by differentiation, however, resulting
in impaired myogenesis. Satellite cell phenotype is defined by the
differential expression of specific factors, among which Pax7,
MyoD and myogenin. While MyoD remains generally detectable,
although at variable levels, high and low expression of Pax7 and
myogenin, respectively, characterizes proliferating satellite cells,
while the opposite pattern defines differentiating cells [43]. The
relevance of TNFa to the regulation of the myogenic program is
demonstrated by studies showing that increased cytokine levels
inhibit skeletal myogenesis both in vivo and in vitro [5,44,45].
Satellite cell activation and differentiation appear required for
the maintenance of skeletal muscle mass [46]. Muscle atrophy
induced in mice by aging or hindlimb suspension is associated
with loss of muscle precursor cells, resulting in reduced
regenerative potential [19]. Recent studies reported that the
skeletal muscle of tumor-bearing mice is markedly infiltrated by
bone marrow-derived stem cells, suggesting the occurrence of a
compensatory mechanism aimed at counteracting the wasting
stimuli [47]. Alterations of the myogenic process were proposed
Figure 4. Follistatin overexpression prevents TNFa-induced MyHC loss without interfering with ERK activation. C2C12 myotubes (5
days differentiation), transfected or not with myc-follistatin (FST) and treated or not with 100 ng/ml TNFa for 48 h. (A) Phase contrast microscopy
showing the hypertrophy induced by FST in cells treated or not with TNFa. (B) Western blots for MyHC, p-ERK and p-Akt protein levels and (C)
corresponding densitometric analysis normalized by tubulin. Data (means 6 SD; n= 3) expressed as percentage of controls. Significance of the
differences: *p,0.05 vs C; $ p,0.05 vs TNFa.
doi:10.1371/journal.pone.0013604.g004
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to play a determinant role in the pathogenesis of muscle atrophy
[5]. Normal mice exposed to TNFa and IFNc combined
developed muscle hypotrophy, associated with decreased MyoD
levels, through a mechanism involving NF-kB [5]. Reduced
MyoD levels, but unchanged NF-kB DNA-binding, were
detected in a TNFa-dependent experimental model of cancer
cachexia [20]. Finally, TNFa was proposed to abrogate satellite
cell function, thereby delaying or inhibiting mice muscle
regeneration after injury [48], and consistently, a reduced
number of regenerating fibers was observed in TNFa-hyperex-
pressing muscles [45].
The present study demonstrates that in the muscle of the C26
hosts Pax7 expression is significantly increased with respect to
controls, while myogenin levels are reduced. In previous reports
Pax7 overexpression was found to result in inhibition of
myogenesis [49]. In this regard, the pattern exhibited by Pax7
and myogenin in the skeletal muscle of C26 hosts is plainly
compatible with an impaired regenerative process and suggests
the possibility that activated satellite cells accumulate in tumor
host muscle because of either enhanced proliferation or impaired
differentiation or both. Altered expression of myogenic factors
was previously reported in AH-130 hepatoma-bearing rats [20],
in cancer patients [50], and in an experimental model of chronic
kidney disease [51]. In the latter report, downregulation of IGF-1
signaling appeared to impair regeneration [51]. The present study
suggests an alternative mechanism based on ERK activation:
when the C26 hosts are treated with PD, and ERK is thus
inhibited, Pax7 and myogenin expression is restored to control
values. These observations suggest that ERK activation likely
contributes to maintain satellite cells in an undifferentiated
state.
The involvement of ERK in impairing the myogenic program
in the muscle of cachectic animals was investigated in details in
differentiating C2C12 myocytes. During differentiation, phos-
phorylated ERK, occurring at high levels over days 1–3,
progressively declines concomitantly with Pax7 reduction and
myogenin and MyoD increases (Fig. S5) [52]. In day 2-
differentiating myocytes exposed to TNFa MyoD and myogenin
decrease, but significantly increase on ERK inhibition. A different
pattern can be observed for Pax7, whose expression in both
differentiating myoblasts (Fig. S5) and terminally differentiated
myotubes is virtually abrogated by TNFa (not shown), this change
being only partially prevented by PD administration. This
observation apparently is in contrast with the pattern shown by
Pax7 in the C26 hosts. A possible explanation could reside in the
multiple actions exerted by Pax7, which not only is required to
promote the proliferation of undifferentiated cells, but is also
necessary for the myogenic differentiation to proceed [53]. ERK-
dependent reduction in Pax7 expression was also shown in
differentiating C2C12 myoblasts treated with myostatin [52].
Figure 5. ERK inhibition restores the myogenic potential in TB mice. (A) Immunostaining of Pax7, laminin and caveolin1 (Cav1) in tibialis
transverse sections of controls and TB mice. (B) Pax7, MyoD and myogenin protein expression in the GSN of controls (n = 6) and TB mice (n = 8) either
untreated or administered PD (1 mg/kg) and (C) corresponding densitometric analysis normalized by tubulin. Data (means 6 SD) are expressed as
percentages of controls. Significance of the differences: **p,0.01 vs C; $ p,0.05 vs C26; $$ p,0.01 vs C26.
doi:10.1371/journal.pone.0013604.g005
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Conclusions
The results shown in the present study demonstrate that ERK
plays a crucial role in the pathogenesis of muscle wasting in cancer
cachexia. ERK activation results in: 1) hyperexpression of the
muscle-specific ubiquitin ligase atrogin-1, suggesting that an
upregulation of UPS activity eventually supports protein hyperca-
tabolism; 2) downregulation of the myogenic process, characterized
by accumulation of activated satellite cells not competent to proceed
into the differentiative program. In the adult tissue, the regenerative
program is a normal response to an antecedent injury, yet the frame
of reference for the modulations of myogenesis in cancer cachexia is
poorly defined. In this regard, a previous study reported the
occurrence of sarcoplasmic membrane leakage in mice bearing the
C26 tumor [54]. Another possibility is that myogenesis is activated
to compensate for a loss of myonuclei [47]. Irrespective of the
stimulus leading to muscle regeneration, however, the observation
that ERK inhibition can rescue satellite cells towards differentiation
offers new clues for a better understanding of the pathogenetic
mechanisms of muscle depletion in cancer cachexia and should be
extensively explored in order to outline molecular targets potentially
relevant to its treatment.
Supporting Information
Figure S1 PD98059 administration (3 mg/kg) counteracts the
onset of cachexia in C26-bearing mice. A) Body weight changes
(i.b.w. of C=18.9361.38 g; C26= 18.0761.06 g; PD=18.246
1.75 g; C26 PD=17.9661.65 g), (B) muscle weight in controls
(n = 6) and C26 hosts (n = 8) either untreated or administered PD
(3 mg/kg). Data (means 6 SD) are expressed as percentages of
controls. Significance of the differences: *p,0.05 vs C; $ p,0.05
vs C26.
Found at: doi:10.1371/journal.pone.0013604.s001 (0.24 MB TIF)
Figure S2 PD98059 administration (3 mg/kg) counteracts the
onset of cachexia in AH-130-bearing rats. A) Body weight
changes, (B) muscle weight in controls (n = 6) and AH-130 hosts
(n = 8) either untreated or administered PD (3 mg/kg, s.c.). Data
(means 6 SD) are expressed as percentages of controls.
Significance of the differences: *p,0.05 vs C; **p,0.01 vs C; $
p,0.05 vs AH-130.
Found at: doi:10.1371/journal.pone.0013604.s002 (0.25 MB TIF)
Figure S3 PD98059 administration does not affect circulating
IL-6 levels in TB mice. IL-6 plasma levels (pg/ml) of TB mice
Figure 6. ERK inhibition promotes myogenic differentiation of C2C12 cells. Subconfluent C2C12 cells switched to DM and simultaneously
treated for 48 h with 100 ng/ml TNFa in the presence or in the absence of PD (20mM). (A) MyHC immunostaining. (B) Protein expression levels of p-
ERK, MyHC, p-Akt, MyoD, myogenin and Pax7. Densitometric quantifications were normalized according to tubulin levels. Data (means 6 SD; n = 3)
expressed as percentages of controls. Significance of the differences: *p,0.05 vs C; **p,0.01 vs C; $ p,0.05 vs TNFa; $$ p,0.01 vs TNFa.
doi:10.1371/journal.pone.0013604.g006
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(n = 8) and controls (n = 6), treated or not with PD (1 mg/kg),
expressed as percentage of controls. Data are means 6 SD.
Significance of the differences: **p,0.01 vs C.
Found at: doi:10.1371/journal.pone.0013604.s003 (0.19 MB TIF)
Figure S4 Myogenin is hyperphosphorylated in the GSN of
C26-bearing mice. Myogenin expression assayed in C (n = 2) and
TB mice (n = 2) on 30 mg of GSN cytosolic proteins, incubated
(309, 37uC) in 2 mM MnCl2, 50 mM HEPES pH 7.5, 0.1 mM
EGTA, 5 mM DTT, in the presence or in the absence of lambda
phosphatase (PPase; 400 U), and heat-denaturated in sample-
loading buffer. Western blotting conducted as described in
Materials and Methods.
Found at: doi:10.1371/journal.pone.0013604.s004 (0.29 MB TIF)
Figure S5 Myogenic differentiation in C2C12 cells is associated
with ERK downregulation. p-ERK, MyHC, MyoD, myogenin
and Pax7 protein levels assayed on protein lysates from growing
myoblasts (‘myobl’) or cells differentiated for 1 to 6 days.
Densitometric quantifications were normalized according to
tubulin levels. Data (means 6 SD; n= 2) are expressed as
percentages of growing myoblasts.
Found at: doi:10.1371/journal.pone.0013604.s005 (0.45 MB TIF)
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